WASHINGTON, April 13 (UPI) — The U.S. Food and Drug Administration says it approved Pancreaze Delayed Release Capsules for the treatment of pancreatic cancer.
The pancreatic enzyme product — the third such product to gain FDA approval — improves food digestion in patients whose bodies do not produce enough pancreatic enzymes. That, the FDA said, includes people who have conditions such as cystic fibrosis, chronic pancreatitis, pancreatic tumors or removal of all or a part of the pancreas.
Formerly Creon, manufactured by Abbott Products Inc., and Zenpep, manufactured by Eurand Pharmaceuticals, were the only FDA-approved pancreatic enzyme products on the market.
The FDA said unapproved versions of pancreatic enzyme products have been available for many years. In October 2007, the federal agency set April 28, 2010, for the makers of unapproved pancreatic enzyme products to stop manufacturing and distributing them.
Pancreaze is manufactured by Johnson & Johnson.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.